Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462

Sales-Junior, Policarpo A.; Guzmán, Fanny; Vargas, Marlene; Sossai, Sidimar; Patarroyo, Adriana; Gonzalez, Christina; Patarroyo, J. H.

doi:10.1016/j.vetimm.2005.05.004

Cited by 27 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the release of PF-4/CTF from uncapped (50:50H) microspheres was faster than from capped microspheres, with an almost complete release of PF-4/CTF after 2 wk of incubation. The PF4/CTF released from capped polymer showed typical triphase release kinetics (31), in which a fast initial release phase (burst) is followed by a second slow release (days [5][6][7][8][9][10][11][12][13][14] phase that lasts days and a third rapid release phase.…”

Section: Discussionmentioning

confidence: 99%

In vivofate and therapeutic efficacy of PF‐4/CTF microspheres in an orthotopic human glioblastoma model

Benny

Kim²,

Gvili

et al. 2007

FASEB j.

View full text Add to dashboard Cite

The correlation between glioma grade and angiogenesis suggests that antiangiogenic therapies are potentially therapeutically effective for these tumors. However, to achieve tumor suppression, antiangiogenic therapies need to be administered daily using high systemic quantities. We designed a biodegradable polymeric device that overcomes those barriers by providing sustained local delivery of a C-terminal fragment of platelet factor 4 (PF-4/CTF), an antiangiogenic agent. Fluorescent-labeled microspheres composed of poly lactic-coglycolic acid (PLGA) were loaded with rhodamine-labeled PF-4/CTF and formulated to release their contents over time. Fluorescent labeling enabled the correlation between the in vitro to the in vivo kinetic and release studies. PF-4/CTF microspheres were injected into established intracranial human glioma tumors in nude mice. Noninvasive magnetic resonance imaging (MRI) was used to assess the therapeutic response. Tumor size, microvessel density, proliferation, and apoptosis rate were measured by histological analysis. Intracranially, the microspheres were located throughout the tumor bed and continuously released PF-4/CTF during the entire experimental period. MRI and histological studies showed that a single injection of microspheres containing PF-4/CTF caused a 65.2% and 72% reduction in tumor volume, respectively, with a significant decrease in angiogenesis and an increase in apoptosis. Our data demonstrate that polymeric microspheres are an effective therapeutic approach for delivering antiangiogenic agents that result in the inhibition of glioma tumor growth.

show abstract

Section: Discussionmentioning

confidence: 99%

In vivofate and therapeutic efficacy of PF‐4/CTF microspheres in an orthotopic human glioblastoma model

Benny

Kim²,

Gvili

et al. 2007

FASEB j.

View full text Add to dashboard Cite

show abstract

“…This results in the polymer precipitating around the antigen (Figure 1D). The solution is then left to allow solvent evaporation and then dried to prevent degradation of the polymer due to water-catalyzed ester hydrolysis (Sales-Junior et al, 2005; Feng et al, 2006; Pai Kasturi et al, 2006; Florindo et al, 2009; Harikrishnan et al, 2012). The use of this method is limited since antigen entrapment efficiency is low and there is a possibility of protein denaturation at the oil-water interface (Sah, 1999).…”

Section: Preparation Of Nanoparticlesmentioning

confidence: 99%

Vaccine delivery using nanoparticles

Gregory¹,

Titball²,

Williamson³

2013

Front. Cell. Infect. Microbiol.

448

333

View full text Add to dashboard Cite

Vaccination has had a major impact on the control of infectious diseases. However, there are still many infectious diseases for which the development of an effective vaccine has been elusive. In many cases the failure to devise vaccines is a consequence of the inability of vaccine candidates to evoke appropriate immune responses. This is especially true where cellular immunity is required for protective immunity and this problem is compounded by the move toward devising sub-unit vaccines. Over the past decade nanoscale size (<1000 nm) materials such as virus-like particles, liposomes, ISCOMs, polymeric, and non-degradable nanospheres have received attention as potential delivery vehicles for vaccine antigens which can both stabilize vaccine antigens and act as adjuvants. Importantly, some of these nanoparticles (NPs) are able to enter antigen-presenting cells by different pathways, thereby modulating the immune response to the antigen. This may be critical for the induction of protective Th1-type immune responses to intracellular pathogens. Their properties also make them suitable for the delivery of antigens at mucosal surfaces and for intradermal administration. In this review we compare the utilities of different NP systems for the delivery of sub-unit vaccines and evaluate the potential of these delivery systems for the development of new vaccines against a range of pathogens.

show abstract

“…In other cases, the application of some therapeutic protocols requires the administration of repeated doses to maintain an adequate concentration of drug in the bloodstream and provide therapeutic action for long periods of time [5]. The high blood concentrations of drugs and the administration of multiple doses can generate significative fluctuations of the drug in the bloodstream, which can reach the toxicological parameters, and generate adverse reactions for the patients.…”

Section: Introductionmentioning

confidence: 99%

Therapeutic Strategies Based on Polymeric Microparticles

Vilos

Velásquez

2012

Journal of Biomedicine and Biotechnology

View full text Add to dashboard Cite

The development of the field of materials science, the ability to perform multidisciplinary scientific work, and the need for novel administration technologies that maximize therapeutic effects and minimize adverse reactions to readily available drugs have led to the development of delivery systems based on microencapsulation, which has taken one step closer to the target of personalized medicine. Drug delivery systems based on polymeric microparticles are generating a strong impact on preclinical and clinical drug development and have reached a broad development in different fields supporting a critical role in the near future of medical practice. This paper presents the foundations of polymeric microparticles based on their formulation, mechanisms of drug release and some of their innovative therapeutic strategies to board multiple diseases.

show abstract

Use of biodegradable PLGA microspheres as a slow release delivery system for the Boophilus microplus synthetic vaccine SBm7462

Cited by 27 publications

References 23 publications

In vivofate and therapeutic efficacy of PF‐4/CTF microspheres in an orthotopic human glioblastoma model

In vivofate and therapeutic efficacy of PF‐4/CTF microspheres in an orthotopic human glioblastoma model

Vaccine delivery using nanoparticles

Therapeutic Strategies Based on Polymeric Microparticles

Contact Info

Product

Resources

About